

APPLIED DNA SCIENCES INC

Form 8-K/A

May 07, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A

Amendment No.1

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 31, 2018

Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware **001-36745** **59-2262718**
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)

50 Health Sciences Drive

Stony Brook, New York 11790

(Address of principal executive offices; zip code)

Registrant's telephone number, including area code:

631-240-8800

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

“Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

“Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

“Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

“Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company “

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

Explanatory Note:

This Form 8-K/A amends the Current Report on Form 8-K, which was originally filed on April 5, 2018 (the “Original 8-K”), solely to correct a typographical error in the descriptive title of Item 7.01 which should read “Regulation FD Disclosure”. The text of Item 7.01 is not changed.

Item 7.01. Regulation FD Disclosure

On March 31, 2018, Applied DNA Sciences, Inc. (the “Company”) entered into a License and Cooperation Agreement and a related Supply Agreement (the “Agreements”) effective March 31, 2018, with Colorcon, Inc. (“Colorcon”) for the use of the Company’s SigNature® molecular tags in Colorcon’s pharmaceutical and nutraceutical product offerings and access to the Company’s associated authentication technologies. The Company issued a press release announcing the Agreements on April 5, 2018. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release issued by Applied DNA Sciences, Inc. dated April 5, 2018 announcing agreements with Colorcon, Inc. (1)

(1) Previously filed as an exhibit to the Original 8-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 7, 2018 APPLIED DNA SCIENCES,
INC.

By: /s/ James A. Hayward
Name: James A. Hayward
Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
<u>99.1</u>	<u>Press Release issued by Applied DNA Sciences, Inc. dated April 5, 2018 announcing agreements with Colorcon, Inc. (1)</u>

(1) Previously filed as an exhibit to the Original 8-K.